Immune modulation therapy in a CRIM-positive and IgG antibody-positive infant with pompe disease treated with alglucosidase Alfa: A case report

JIMD Reports

Volumn 2, Issue , 2012, Pages 11-15

  Markic, Josko ^a   Polic, Branka ^a   Kuzmanic Samija, Radenka ^a   Marusic, Eugenija ^a   Stricevic, Luka ^a   Metlicic, Vitomir ^a   Mestrovic, Julije ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

Author keywords

Antibody titer; Enzyme replacement therapy; Glycogen storage disease; Left ventricular mass index; Pompe disease

Indexed keywords

EID: 84881145296     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2011_34     Document Type: Chapter

References (16)

1. Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL et al (2001) Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 3:132–138
2. Ausems MG, Verbiest J, Hermans MP, Kroos MA, Beemer FA, Wokke JH et al (1999) Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet 7:713–716
3. Chien YH, Chiang SC, Zhang XK, Keutzer J, Lee NC, Huang AC et al (2008) Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics 122:e39–45
4. Hirschhorn R, Reuser A (2001) Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3389–3420
5. Joseph A, Munroe K, Housman M, Garman R, Richards S (2008) Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin Exp Immunol 152:138–146
6. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D (2006a) A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148:671–676
7. Kishnani PS, Nicolino M, Voit T, Rogers RC, Tsai AC, Waterson J et al (2006b) Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 149:89–97
8. Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL et al (2007) Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68:99–109
9. Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S et al (2010) Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99:26–33
10. Lipinski SE, Lipinski MJ, Burnette A, Platts-Mills TA, Wilson WG (2009) Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa. Mol Genet Metab 98:319–321
11. Martiniuk F, Chen A, Mack A, Arvanitopoulos E, Chen Y, Rom WN et al (1998) Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet 79:69–72
12. Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS (2009) Elimination of antibodies to recombinant enzyme in Pompe’s disease. N Engl J Med 360:194–195
13. Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, Freyer DR et al (2009) Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 11:210–219
14. Rohrbach M, Klein A, Köohli-Wiesner A, Veraguth D, Scheer I, Balmer C et al (2010) CRIM-negative infantile Pompe disease: 42-month treatment outcome. J Inherit Metab Dis 33:751–757
15. van der Ploeg AT, Reuser AJ (2008) Pompe’s disease. Lancet 372:1342–1353
16. van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ et al (2010) A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 362:1396–1406